Ron Lanton Discusses Moderna mRNA Regulatory Uncertainty with Pharmaceutical Executive

Ron Lanton spoke with Pharmaceutical Executive about regulatory uncertainty surrounding Moderna’s mRNA influenza vaccine review and what it could signal for the broader biotechnology sector. The discussion focused on how shifts in regulatory signals can influence market confidence in platform technologies such as mRNA and whether those signals could affect the development strategies of other manufacturers. Listen to the discussion here.